Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.67 |
| ▸ | EGFR | P00533 | 10/20 | 0.67 |
| ▸ | ABL1 | P00519 | 9/20 | 0.67 |
| ▸ | ABL2 | P42684 | 9/20 | 0.67 |
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | CDK1 | P06493 | 3/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 2/20 | 0.54 |
| ▸ | ADK | P55263 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388001 | 0.90 | PIK3CD (0.61) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL7005521 | 0.88 | LCK (0.72) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL18044717 | 0.88 | KDR (0.59) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL13020096 | 0.85 | SRC (0.69) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL26110170 | 0.85 | AXL (0.63) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL23917434 | 0.85 | SRC (0.61) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL30582589 | 0.85 | AXL (0.63) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL5016910 | 0.84 | PIK3CD (0.65) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL23732756 | 0.83 | SRC (0.65) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22676745 | 0.82 | SRC (0.67) | SRCEGFRABL1ABL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | SRC 87/4885EGFR 432/4885ABL1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.